MarketCap
Akari Therapeutics, Plc AKTX
$ 10.25
0.09%
Facebook
X
Telegram
Akari Therapeutics, Plc Interest Expense | AKTX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Akari Therapeutics, Plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 K | -3 K | -19 K | 368 K | - | - | - | - | - | - | 3.05 M | 5.44 K | -14 K | -601 K | 128 K | 117 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.05 M | -601 K | 314 K |
Quarterly Interest Expense Akari Therapeutics, Plc
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | 2007-Q4 | 2006-Q4 | 2005-Q4 | 2004-Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 100 K | - | - | - | - | 51 K | -2 K | - | -22 K | -13 K | -11 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.05 M | 2.61 K | 4.56 K | - | 2.88 K | 101 K | 143 K | - | - | - | - | - | - | - | - | - | - | - | - | 117 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.05 M | -22 K | 271 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
2.89 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-2.71 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Aclaris Therapeutics
ACRS
|
8.51 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
22.7 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Evelo Biosciences
EVLO
|
61 K | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M | USA |
 |
Clovis Oncology
CLVS
|
53 K | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
8.18 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-309 K | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
-212 K | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
5.47 M | - | -9.21 % | $ 2.55 M | USA |
 |
89bio
ETNB
|
5.29 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M |  Britain |
 |
Fusion Pharmaceuticals
FUSN
|
762 K | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
7.27 K | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
1.12 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
4.04 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-5.32 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-11 K | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
2.92 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-3.25 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
21.4 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-20 K | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
36.8 K | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
348 K | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-170 K | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
2.84 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
3.89 M | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
1.2 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
733 K | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
1.07 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
683 K | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-191 K | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
1.24 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
19.2 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-69.2 K | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
2.67 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
1.3 M | - | -37.48 % | $ 476 K | USA |
 |
ObsEva SA
OBSV
|
3.16 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
210 K | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
20.9 K | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
33 K | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
2.13 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
3.08 M | - | 1.02 % | $ 90.8 M | Britain |